Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 23Active not recruiting 10Completed 4Not yet recruiting 2Terminated 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

pembrolizumab 29Carboplatin 15Cisplatin 13Nivolumab 12atezolizumab 10Radiotherapy 10Paclitaxel 10Ipilimumab 10venetoclax 9Pemetrexed 9Docetaxel 9durvalumab 8Gemcitabine 8fludarabine 7Specimen Handling 7Cyclophosphamide 7Bevacizumab 7tislelizumab 6fludarabine phosphate 6Trastuzumab 6Practice Guidelines as Topic 6Cetuximab 6Biopsy 6enzalutamide 5Surveys and Questionnaires 5Standard of Care 5Radiosurgery 5Magnetic Resonance Spectroscopy 5Dexamethasone 5Cytarabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × exemestane × 90 days × Clear all
NCT06630325 2026-04-28

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
6 enrolled 3 charts
GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡